16 results about "STREPTOCOCCAL INFECTIONS" patented technology

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising such immunogenic compositions and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not present and / or in. The invention also relates to vaccination of human individuals, especially infants and elderly people, against Streptococcus pneumoniae infection using such novel immunogenic compositions.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

Methods, compositions and kits for detecting Group A Streptococcus in a biological sample are described. More particularly, the present disclosure provides an immunoassay in which the specificity of detection of Group A Streptococcus is enhanced by addition of N-acetyl-D-glucosamine. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of streptococcal infection in a human subject.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition which comprises glucocorticoid and penicillin. Aiming at the problems of poor treatment effect, poor prognosis and the like of clinically treating swine streptococcal meningitis at present, penicillin and glucocorticoid are combined, and meanwhile, the invention discloses a drug combination method. Microscopic examination, change of partial bacteria loading amount, blood brain barrier staining observation and the like are carried out to find that the composition can effectively treat streptococcus suis infection and can quickly reduce brain inflammation, so that the blood brain barrier damaged by streptococcus suis is repaired, and the effect is better than that of a single component; therefore, the prognosis effect of streptococcal meningitis of swine can be improved to the greatest extent. Meanwhile, the composition is a common medicine, and a new feasible thought is provided for clinically treating the streptococcus suis diseases.

A fusion protein vaccine for inhibiting group A streptococcal infection and its application, belonging to the field of biomedical technology. In order to solve the technical problems of high vaccine price, low safety and effectiveness of group A streptococcal vaccines in the prior art, the present invention provides a fusion protein vaccine for inhibiting group A streptococcal infection, wherein the amino acid sequence of the fusion protein in the fusion protein vaccine is shown in SEQ ID NO.1; the fusion protein vaccine can induce a high level of specific antibodies, and the antibodies have no cross-reaction with human heart, brain, and kidney tissues, and effectively protect mice against M12 type GAS infection. The fusion protein vaccine provided by the present invention can be used to prepare drugs for inhibiting group A streptococcal infection, has the advantages of targeting the Chinese epidemic strain, high safety, and simple use, and is easy to promote and use.

The invention discloses a novel antibacterial peptide based on deep learning identification and application thereof, and relates to the technical field of biology.The identification method comprises the steps that high-throughput precise mining is conducted on South Ocean microorganism metagenome source antibacterial peptides through deep learning, 10 representative candidate antibacterial peptides cAMP are focused, and the molecular weight of the antibacterial peptide cAMP is increased; and two lead compounds which have low hemolytic activity and low cytotoxicity and act on streptococcus pyogenes infection are obtained by adopting a chemical synthesis strategy, namely antibacterial peptides Southernin 36 and Southernin 134 with novel structures. Detailed pharmacological studies including in-vitro bacteriostatic activity, cytotoxicity and hemolytic activity, mouse epidermis infection model antibacterial activity study, bacteriostatic mechanism analysis and the like are carried out, and the application of the compound in preparation of antibacterial drugs is also carried out. The two novel antibacterial peptides Southernin 36 and Southernin 134, which are obtained by the invention and are derived from Southern Ocean microbiome, have a relatively good industrial application prospect.

Disclosed are methods of treating and / or inhibiting an intramammary infection in a mammalian subject. The methods included administering a therapeutically effective amount of surface-associated polypeptides from various bacteria. Also disclosed are methods for blocking or reducing infection in a mammal. Further disclosed are methods for reducing the rate of intra-mammary infection and / or mastitis in a dairy mammal. Methods of increasing milk production are also provided.

The invention discloses a tilapia streptococcus antigen protein and preparation and application of a segmented subunit nano-carrier vaccine of the tilapia streptococcus antigen protein, and belongs to the technical field of biological medicine. The invention discloses a preparation method of BNC-rEno (B-rE) and a segmented nano-carrier soaking vaccine (B-rE1 / B-rE2 / B-rE3) of the BNC-rEno (B-rE). The invention further discloses an immune protection effect of the subunit nano vaccine on tilapia mossambica to resist streptococcus infection. According to the Eno segmented subunit nano vaccine (B-rE3) disclosed by the invention, the serum antibody level of tilapia is remarkably improved, the death rate of tilapia infected with streptococcus agalactiae and streptococcus iniae is remarkably reduced, and the Eno segmented subunit nano vaccine has a relatively good immune protection effect on tilapia against streptococcus infection, can be used as a potential candidate vaccine for tilapia against streptococcus infection, and can be used for preparing the tilapia vaccine for preventing streptococcus infection. A new thought and an effective choice are provided for immune prevention and control of tilapia streptococcosis.

The present disclosure generally relates to autoimmune diseases, disorders and conditions associated with a Group A Streptococcus infections and methods of treating or preventing such diseases, disorders or conditions, or more particularly rheumatic fever, rheumatic heart disease and Sydenham's chorea.